ClinicalTrials.gg
RecruitingNCT06868381Updated Nov 19, 2026

A Trial of Baricitinib in Patients With Cardiac Sarcoidosis

A Phase 2 interventional study of Baricitinib (LY3009104) 4 mg in Cardiac Sarcoidosis, sponsored by Stanford University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Stanford University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Nov 19, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 115 studies in Sarcoidosis with a site in United States — 23 open to participants now, 25 under way, 3 of them phase 3. Sarcoidosis · United States.

Planned enrollment
47th of 69
10 · median 16
Started
2026
with 3 others
Phase 2
26 of 115
4 open now
Primary completion
2028-07
later than 13 of 24 live
Registered
109th of 115
by date

Among the 115 studies in Sarcoidosis with a site in United States, this one is the 47th largest by planned enrollment of the 69 interventional ones that give a count, is one of 4 that started in 2026, is one of 26 in phase 2, reaches primary completion later than 13 of the 24 other live ones, and was the 109th registered.

Sarcoidosis

271 studies on the registry are indexed under Sarcoidosis; 51 are open to participants now.

Browse Sarcoidosis studies →

Open to participants now

23 of the 115 studies in Sarcoidosis with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Sarcoidosis studies recruiting now, 30 (73%) set no upper age limit and 1 (2%) stops at 75 or younger; 6 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies in Sarcoidosis with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if baricitinib in combination with a background steroid-sparing medication can treat active cardiac sarcoidosis in adults. The main question it aims to answer is:

- In patients with active cardiac sarcoidosis, does treatment with baricitinib improve cardiac sarcoidosis disease activity as assessed by changes on cardiac FDG-PET/CT?

Participants will:

  • Take baricitinib in combination with a steroid-sparing therapy for up to 16 weeks
  • Visit the clinic every two to four weeks for checkups and tests
  • Be asked to complete questionnaires to see how they feel on baricitinib and medication diaries to record when they take baricitinib
03

Conditions studied

  • Cardiac Sarcoidosis

Browse trials for

Keywords

  • baricitinib
  • sarcoidosis
  • cardiac sarcoidosis
  • Janus kinase inhibitor
  • JAK inhibitor
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of cardiac sarcoidosis based on one of the following pathways:

    • Histological Diagnosis

      • Myocardial or extracardiac demonstrating non-caseating granuloma with no alternative cause identified AND
      • Abnormal FDG uptake on cardiac PET-CT conducted within six weeks of Screening, in a pattern consistent with active cardiac sarcoidosis AND
      • Exclusion of other causes for cardiac manifestations
    • Clinical Diagnosis

      • One or more of the following is present:

        • +/- responsive cardiomyopathy or heart block
        • Unexplained reduced (\< 40%) and/or segmental wall motion abnormalities not related to coronary artery disease or another defined cause
        • Unexplained sustained (spontaneous or induced) VT
        • Mobitz type II 2nd degree heart block or 3rd degree heart block
        • CT chest and/or FDG PET-CT showing features consistent with pulmonary sarcoidosis and/or hilar lymphadenopathy AND
      • Abnormal FDG uptake on cardiac PET-CT conducted within 6 weeks of Screening, in a pattern consistent with active cardiac sarcoidosis AND
      • Exclusion of other causes for cardiac manifestations
  • Active cardiac sarcoidosis based on abnormal FDG uptake on cardiac PET-CT conducted within six weeks of Screening, in a pattern consistent with active cardiac sarcoidosis
  • No current treatment with immunosuppressive medications other than a steroid-sparing medication (including methotrexate, leflunomide, azathioprine, or mycophenolate mofetil), and/or prednisone (or equivalent) at a dose of ≤ 20mg daily at Baseline

Key Exclusion Criteria:

  • Receipt of a non-biologic DMARD or immunosuppressive agent other than methotrexate, leflunomide, azathioprine, mycophenolate mofetil, hydroxychloroquine, or glucocorticoids within 28 days prior to screening
  • Receipt of a bDMARD or tsDMARD, including non-depleting B-cell-directed therapy (eg, belimumab), T cell costimulatory blockade (eg, abatacept), TNF-alpha inhibition (eg, infliximab, adalimumab, etanercept, golimumab, certolizumab pegol), interleukin-6 inhibition (eg, tocilizumab, sarilumab), interleukin-1 inhibition (eg, anakinra), JAK inhibition (eg, tofacitinib, upadacitinib, baricitinib), or other biologic immunomodulatory agent within 28 days prior to screening
  • Receipt of any biologic B cell-depleting therapy (eg, rituximab, ocrelizumab, obinutuzumab, ofatumumab, inebilizumab) in the 6 months prior to screening; receipt of such a B cell-depleting agent in the period 6-12 months prior to screening is exclusionary unless B cell counts have returned to ≥ LLN
  • History of venous thromboembolism (VTE) or an increased risk for VTE
  • Current smoking
  • Estimated \< 30 mL/min/1.73 m2 by Modification of Diet in Renal Disease Study (MDRD) equation
  • Blood tests at screening that meet any of the following criteria:

    • \< 7.5 g/dL
    • Neutrophils \< 1000/mm3
    • Absolute lymphocyte count \< 500/mm3
    • \< 100 x 109/L
  • Subjects with the following abnormal liver function tests:

    • (AST) > 2x
    • Alanine aminotransferase (ALT) > 2x ULN
    • Total (TBL) > 2x ULN unless AST, ALT, and hemoglobin are within central laboratory normal range and the patient has a known history of Gilbert syndrome
  • Active, infection at the time of Screening
  • Active or history of malignancy that was active within the last 5 years, except as follows:

    • In situ carcinoma of the cervix following apparently curative therapy > 12 months prior to screening,
    • Cutaneous basal cell or squamous cell carcinoma following apparently curative therapy, or
    • Prostate cancer treated with radical prostatectomy or radiation therapy with curative intent > 3 years prior to screening and without known recurrence or current treatment
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    baricitinib + steroid-sparing drug +/- glucocorticoid taper

    * Participants will be treated with baricitinib 4 mg daily for up to 16 weeks in combination with a background steroid sparing medication * Participants who are on steroids at the time of enrollment will continue the steroid at a dose of prednisone (or equivalent) ≤ 20mg PO daily at Baseline and complete an 8 week taper of their steroid medication per a standardized protocol

    Drug: Baricitinib (LY3009104) 4 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of patients with resolution of cardiac FDG uptake on PET-CT

    Resolution of FDG uptake will be determined by the consensus of two blinded nuclear medicine radiologists, in accordance with current SNMMI and ASNC guidelines

    Time frame: From baseline to end of treatment at 16 weeks

Secondary outcomes

  1. Percent change in FDG avidity (SUVmax) in the cardiac lesion with greatest FDG avidity on PET-CT

    Time frame: From baseline to 8 weeks and end of treatment at 16 weeks

  2. Percent change in total cardiac metabolic activity on FDG PET-CT

    Total cardiac metabolic activity is total lesion glycolysis within the heart

    Time frame: From baseline to 8 weeks and end of treatment at 16 weeks

  3. Proportion of patients with resolution of extracardiac FDG uptake on PET-CT

    Time frame: From baseline to 8 weeks and end of treatment at 16 weeks

  4. Percent change in FDG avidity (SUVmax) in up to six extracardiac lesions on PET-CT

    Time frame: From baseline to 8 weeks and end of treatment at 16 weeks

  5. Percent change in total extracardiac metabolic activity on FDG PET-CT

    Total extracardiac metabolic activity is total lesion glycolysis of extracardiac disease

    Time frame: From baseline to 8 weeks and end of treatment at 16 weeks

  6. Proportion of patients with resolution of cardiac FDG uptake on PET-CT

    Time frame: From baseline to 8 weeks and end of follow-up at 28 weeks

  7. Change in sarcoidosis disease activity assessment

    Sarcoidosis disease activity assessed with King's Sarcoidosis Questionnaire. Total score range: 0 to 100, with 100 indicating the highest quality of life

    Time frame: From baseline to 8 weeks and end of treatment at 16 weeks

  8. Change in fatigue assessment

    Fatigue assessed with FACIT-F. Total score range: 0-52, lower scores correspond with more fatigue

    Time frame: From baseline to 8 weeks and end of treatment at 16 weeks

  9. Change from Baseline in Physician Disease Activity Visual Analogue Scale (VAS)

    Physician rates patient's disease on a 100 mm VAS. Score range: 0 to 100, higher scores correspond to worse disease state

    Time frame: From baseline to 8 weeks and end of treatment at 16 weeks

  10. Change from Baseline in Patient Disease Activity Visual Analogue Scale (VAS)

    Patient rates their disease on a 100 mm VAS. Score range: 0 to 100, higher scores correspond to worse disease state

    Time frame: From baseline to 8 weeks and end of treatment at 16 weeks

  11. Changes in ACE laboratory assessment

    Time frame: From baseline to 8 weeks and end of treatment at 16 weeks

  12. Changes in high-sensitivity troponin I laboratory assessment

    Time frame: From baseline to 8 weeks and end of treatment at 16 weeks

  13. Changes in NT-proBNP laboratory assessment

    Time frame: From baseline to 8 weeks and end of treatment at 16 weeks

  14. Changes in total IgG laboratory assessment

    Time frame: From baseline to 8 weeks and end of treatment at 16 weeks

  15. Changes in ESR laboratory assessment

    Time frame: From baseline to 8 weeks and end of treatment at 16 weeks

  16. Changes in CRP laboratory assessment

    Time frame: From baseline to 8 weeks and end of treatment at 16 weeks

  17. Number of participants with safety endpoints of interest

    Safety endpoints of interest include hospitalization for cardiac events, implantation of a left ventricular assist device (LVAD), cardiac transplantation, mortality

    Time frame: From screening to end of follow-up at 28 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Jul 2028, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2025
First posted
Mar 10, 2025
StartActual
Apr 1, 2026
Primary completionEst.
Jul 1, 2028
CompletionEst.
Dec 1, 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 19, 2026
Sites
Stanford University is now Recruiting
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Not yet recruiting→Recruiting
    Stanford University is now Recruiting
    + 3 other changes: verification date, date precision and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06868381
Responsible party
Matthew C. Baker (Associate Professor of Medicine, Stanford University) — Principal investigator
First posted
Mar 10, 2025
Start date
Apr 1, 2026
Primary completion
Jul 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

Angie Aberia
Contact
aberia@stanford.edu
650-723-8516
Travis Deal
Contact
tdeal1@stanford.edu
Matthew C Baker, MD, MS
principal investigator · Stanford University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion